Bristol-Myers Squibb Eyes A Jewel To Add To Its String Of Pearls
This article was originally published in The Pink Sheet Daily
Executive Summary
$4.5 billion cash takeover of ImClone would give BMS 100 percent of North American Erbitux sales that totaled $700 million in the first half.